GlobeNewswire Inc | Jan 5, 2021 08:30AM EST

January 05, 2021

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in the H.C. Wainwright Virtual BioConnect 2021 Conference to be held January 11-14, 2021 and the LifeSci Advisors 10th Annual Corporate Access Event to be held January 6-14, 2021.

The virtual LifeSci Advisors event presentation will be live at 12:00 pm EST on January 8, 2021 from the Albireo Media and Investors page ir.albireopharma.com and the H.C. Wainwright fireside chat will be available beginning Monday, January 11, 2021 also at ir.albireopharma.com. Both sessions will be archived and available for replay on Albireos website for two weeks following the events.

About AlbireoAlbireo Pharmais a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireos lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZenecain 2008 and is headquartered inBoston,Massachusetts, with its key operating subsidiary inGothenburg,Sweden. TheBoston Business Journalnamed Albireo one of the 2020 Best Places to Work inMassachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.

Media & Investor contacts:Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.comHans Vitzthum, LifeSci Advisors, LLC., 857-272-6177